📰 Nasdaq Edit News
Page 3 - Nasdaq Edit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.
October 4, 2023
Brave Asset Management Inc. acquired a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,725 shares of the company’s stock, valued at approximately $88,000. A number of other hedge funds have also modified […]
October 2, 2023
Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat reports. They currently have $17.00 target price on the stock, up from their prior target price of $9.00. Other equities research analysts have also recently issued research reports […]
October 2, 2023
Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. They currently have $17.00 target price on the stock, up from their previous target price of $9.00. A number of other research analysts have also weighed in […]
September 26, 2023
Editas Medicine (NASDAQ:EDIT – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Institutional & Insider Ownership 76.6% of Editas […]
September 1, 2023
Profund Advisors LLC purchased a new position in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 125,742 shares of the company’s stock, valued at approximately $912,000. Profund Advisors LLC owned 0.18% of Editas Medicine at the […]
August 18, 2023
StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report released on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the subject of a number of other research reports. Oppenheimer reissued a market perform rating and set a $12.00 price objective on shares of […]
August 18, 2023
StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the topic of a number of other research reports. Raymond James upgraded Editas Medicine from a market perform rating to an outperform rating and […]
August 12, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Cantor Fitzgerald upped their FY2023 earnings estimates for Editas Medicine in a report issued on Tuesday, August 8th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will post earnings per share of ($2.35) for the year, up from their prior estimate of ($2.43). […]
August 6, 2023
Oppenheimer restated their market perform rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $12.00 price target on the stock. EDIT has been the subject of a number of other research reports. StockNews.com lowered Editas Medicine from a hold […]
August 5, 2023
Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective cut by Chardan Capital from $22.00 to $19.00 in a report published on Wednesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. EDIT has been the topic of a number of other reports. Raymond James upgraded shares of Editas Medicine […]